Ten Bridge Communications

Strategic communications partner for emerging biotech companies

United States

Est. 2015

1-10 employees

Visit Website

Verified

11+ Yrs

About Ten Bridge Communications

Ten Bridge Communications is a specialized communications agency serving the biotechnology sector. Established in 2015, the firm focuses on helping biotech companies translate scientific innovation into strategic visibility, partnerships, and market impact. Their tagline "Biotech's communications partner" reflects a decade-long commitment to the life sciences industry.

The agency offers comprehensive communications support through their NewCo Studio, which provides launch strategy and brand development for emerging biotechnology companies. Their client portfolio includes gene therapy developers, antibody therapeutics companies, RNA editing platforms, and biosciences research institutes. The firm's work spans media relations, corporate positioning, and strategic communications counsel tailored to the unique challenges of early-stage biotech ventures.

Recent client achievements include major financing announcements ranging from $107 million to $305 million Series B rounds, positive clinical trial data releases, and successful company launches. The agency has worked with companies advancing novel therapeutic modalities including gene editing, bispecific antibodies, and peptide therapeutics.

Best For

Early-stage and emerging biotechnology companies seeking to establish market presence, attract investment, and build strategic partnerships. Well-suited for startups developing novel therapeutic platforms, research institutes advancing innovation, and pre-clinical to clinical-stage companies requiring sophisticated scientific communications expertise.

Key Strengths

Deep biotech sector specialization with 10 years focused exclusively on biotechnology communications
NewCo Studio offering demonstrates structured approach to company launch strategy and brand development
Track record supporting significant financing rounds ($100M+ Series B closings) and clinical milestone announcements
Portfolio includes clients advancing cutting-edge modalities including gene editing, RNA therapeutics, and protein degradation platforms
Experience translating complex scientific innovations into strategic communications narratives for investors and partners

Why Choose Ten Bridge Communications

Choose Ten Bridge Communications when launching a biotech company or advancing through critical inflection points requiring sophisticated scientific storytelling. Their specialized expertise serves companies that need communications partners who understand complex therapeutic modalities, investor expectations, and the biotechnology ecosystem.

Expect a strategic partnership model focused on building company visibility, positioning for partnerships, and translating scientific progress into market impact. Their NewCo Studio suggests structured methodologies for emerging companies establishing market presence.

Healthcare Focus

Ten Bridge Communications operates exclusively within the biotechnology and life sciences sector, serving pharmaceutical development companies, research institutes, and therapeutic platform developers. Their healthcare specialization centers on translating cutting-edge biomedical research and drug development into strategic communications that resonate with investors, scientific communities, and business development partners in the biopharma ecosystem.

Ideal Client Profile

Venture-backed biotechnology startups in seed through Series B stages developing novel therapeutic platforms. Companies advancing innovative science including gene editing, cell therapy, antibody engineering, or RNA therapeutics that require communications partners fluent in complex biology and capable of articulating scientific differentiation to investors, partners, and media.